Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals (Nasdaq: XENE) announced inducement equity grants to seven new non-officer employees totaling 77,750 share options with an exercise price of $39.20 per share, equal to the closing price on the grant date.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenon Pharmaceuticals (Nasdaq: XENE) announced inducement equity grants to seven new non-officer employees totaling 77,750 share options with an exercise price of $39.20 per share, equal to the closing price on the grant date. Grants were approved by the Compensation Committee with an effective date of October 2, 2025 and are intended as inducements under Nasdaq Listing Rule 5635(c)(4). Options vest over four years (25% at one year, then monthly 1/36th) and have a 10-year term, subject to the company’s 2025 Inducement Equity Incentive Plan and standard option agreement terms.
Business context: Xenon is a neuroscience-focused biopharmaceutical company advancing azetukalner in Phase 3 for epilepsy, MDD, and BPD and early-stage Kv7 and Nav1.7 programs in Phase 1 for pain.
Details
News Market Reaction – XENE
On Oct 8, the first trading day after this news, XENE closed 0.23% above the previous close.
Data tracked by StockTitan Argus for the Oct 8 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, British Columbia and BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 77,750 share options. All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of October 2, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X. “Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contact:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
Media: media@xenon-pharma.com
Investors: investors@xenon-pharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.